Drug Profile
Perflutren - Molecular Biosystems
Alternative Names: FS-069; Octafluoropropane; Optison; PerfluoropropaneLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Molecular Biosystems
- Developer Chugai Pharmaceutical; GE Healthcare; Molecular Biosystems; OncoGenex Pharmaceuticals
- Class Contrast media; Diagnostic agents; Fluorocarbons
- Mechanism of Action Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Left ventricular dysfunction
Most Recent Events
- 27 Feb 2023 Perflutren licensed to Sono Thera worldwide
- 25 Jun 2009 CHMP of the EMEA recommends the lifting of the suspension of the marketing authorisation for Perflutren in the European Union
- 21 Aug 2008 OncoGenex Technologies has merged with Sonus Pharmaceuticals to form OncoGenex Pharmaceuticals